Novo Nordisk: A Tactical Long Against Excessive Pessimism
Novo Nordisk (NVO) has been punished by accelerating competition and pricing pressure in the GLP-1/obesity market. At $49.20 the stock prices in a deep growth scare and a guidance cut, but the business still generates meaningful cash flow, pays a 2.48% dividend and controls valuable franchises. This trade idea lays out a mid-term (45 trading days) …